Moffitt Cancer Center Support Grant

莫菲特癌症中心支持补助金

• 批准号: 7581156
• 负责人: William Steven Dalton
• 金额: $ 12.5万
• 依托单位: H. LEE MOFFITT CANCER CTR & RES INST
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-02-18 至 2012-01-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7581156
• 关键词: Ambulatory Care Facilities; Anniversary; Beds; Biometry; Cancer Center; Cancer Center Support Grant; Cell Therapy; Chemistry; Clinical Investigator; Clinical Research; Clinical Trials; Comprehensive Cancer Center; Coupled; Detection; Educational Activities; Enrollment; Faculty; Florida; Flow Cytometry; Funding; Grant; Growth; Health behavior outcomes; Hospitals; Immunology; Informatics; Inpatients; Institution; Intervention; Laboratories; Leadership; Malignant Neoplasms; Microscopy; Minority; Mission; Molecular Biology; Monitor; Numbers; Patients; Peer Review; Phase; Physicians; Population; Prevention; Proteomics; Protocols documentation; Publications; Puerto Rico; Rate; Research; Research Infrastructure; Research Institute; Research Personnel; Research Support; Resource Sharing; Review Committee; Risk; Risk Assessment; Scholarship; Scientist; Screening procedure; Services; Statutes and Laws; Survey Methodology; System; Taxes; Therapeutic; Tissues; Translational Research; Universities; Visit; base; cancer prevention; drug discovery; high throughput screening; innovation; intervention program; medical schools; member; molecular oncology; mouse model; oncology; outreach; programs

Twenty years after opening, the H. Lee Moffitt Cancer Center & Research Institute is submitting its second competitive renewal application for its Cancer Center Support Grant for grant years 10 through 14. The Center's mission remains solely focused on "contributing to the prevention and cure of cancer." The Moffitt Cancer Center, a freestanding, not-for-profit corporation located on the University of South Florida campus in Tampa, Florida, includes a research institute coupled with a 162-bed inpatient facility, an active outpatient clinic with more than 200,000 patient visits per year, a high-risk screening and prevention center, a dedicated Clinical Research Unit for early phase studies, an affiliate network of Florida hospitals and oncology practices and a wide array of outreach and educational activities. The Cancer Center has five scientific programs, all with a translational focus; 14 shared resources (five newly proposed), and a research infrastructure that supports innovative, translational research and enhances interactions among basic scientists, population-based scientists and clinical investigators. Research programs include Molecular Oncology & Drug Discovery, Immunology, Experimental Therapeutics, Risk Assessment, Detection & Intervention, and Health Outcomes & Behavior. Shared resources include Flow Cytometry, Molecular Biology, Microarray, Proteomics, High Throughput Screening & Chemistry, Mouse Models, Analytic Microscopy, Tissue, Cell Therapies, Survey Methods, Informatics, Biostatistics, Clinical Research Support Services and the Clinical Trials Laboratory Core. The Protocol Review & Monitoring System includes two Scientific Review Committees and a separate Protocol Monitoring Committee. Protocol specific support for a large-volume early phase clinical trial portfolio is also requested. During the period since designation as an NCI Comprehensive Cancer Center and the current CCSG submission (2001-2006), the Center has more than doubled its peer reviewed funding and increased NCI funding from $10.6 million to $29 million total dollars; increased accrual to phase I investigator-authored clinical trials from 130 to 534 annually and enrollment on all trials to more than 6,000; opened the Stabile Research Building to nearly double available research space; and created a network of 16 affiliate hospitals and 380 physicians throughout Florida. The Center's 135 members collaborate extensively with 25% of total publications being inter-programmatic.

开放后二十年，H。LeeMoffitt癌症中心与研究所正在提交第二 竞争性更新申请其癌症中心支持赠款10年至14年。 中心的任务仍然完全专注于“为预防和治愈癌症做出贡献”。莫菲特 癌症中心，位于南佛罗里达大学校园的独立，非营利性公司 佛罗里达州坦帕（Tampa）包括一家研究所，加上162张床的住院设施，这是一种活跃的门诊病人 诊所每年有超过200,000例患者就诊，一个高风险筛查和预防中心，专用 早期研究的临床研究部门，佛罗里达州医院和肿瘤学的会员网络 实践以及各种各样的外展和教育活动。 癌症中心有五个科学计划，所有这些计划都以翻译为重点。 14个共享资源（五个 新提出的），以及支持创新，转化研究和 加强基础科学家，基于人群的科学家和临床研究人员之间的相互作用。 研究计划包括分子肿瘤学和药物发现，免疫学，实验疗法， 风险评估，检测和干预以及健康成果与行为。共享资源包括 流式细胞仪，分子生物学，微阵列，蛋白质组学，高吞吐量筛查和化学， 小鼠模型，分析显微镜，组织，细胞疗法，调查方法，信息学，生物统计学， 临床研究支持服务和临床试验实验室核心。协议审查＆ 监视系统包括两个科学审查委员会和一个单独的协议监控 委员会。还请求对大批量的早期临床试验组合的特定方案支持。 自称为NCI综合癌症中心和当前CCSG以来的此期间 提交（2001-2006），该中心的同行审查资金增加了一倍以上，并增加了NCI 资金从1060万美元到290万美元的总资金； I阶段研究者的累计增加了 每年130至534次临床试验，并入学所有试验，超过6,000；打开稳定 研究大楼几乎是两倍可用的研究空间；并创建了16家会员医院的网络 以及整个佛罗里达州的380位医生。该中心的135名成员广泛合作，总计25％ 出版物是跨编程的。